Page last updated: 2024-10-28

fasudil and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

fasudil has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Burthem, J1
Rees-Unwin, K1
Mottram, R1
Adams, J1
Lucas, GS1
Spooncer, E1
Whetton, AD1

Other Studies

1 other study available for fasudil and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells.
    Leukemia, 2007, Volume: 21, Issue:8

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Antigens, CD34; Benzamides; Cell Proliferatio

2007